104 related articles for article (PubMed ID: 33222758)
21. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.
Friedman AA; Xia Y; Trippa L; Le LP; Igras V; Frederick DT; Wargo JA; Tanabe KK; Lawrence DP; Neuberg DS; Flaherty KT; Fisher DE
Clin Cancer Res; 2017 Aug; 23(16):4680-4692. PubMed ID: 28446504
[No Abstract] [Full Text] [Related]
22. A microfluidics platform for combinatorial drug screening on cancer biopsies.
Eduati F; Utharala R; Madhavan D; Neumann UP; Longerich T; Cramer T; Saez-Rodriguez J; Merten CA
Nat Commun; 2018 Jun; 9(1):2434. PubMed ID: 29934552
[TBL] [Abstract][Full Text] [Related]
23. Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
Bellat V; Verchère A; Ashe SA; Law B
BMC Cancer; 2020 Jul; 20(1):661. PubMed ID: 32678032
[TBL] [Abstract][Full Text] [Related]
24. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
[TBL] [Abstract][Full Text] [Related]
25. [Methodology and limitations of pre-clinical models for the development of anticarcinogenic chemotherapy combinations].
Vassal G
Bull Cancer; 1998 Nov; 85(11):929-34. PubMed ID: 9951420
[TBL] [Abstract][Full Text] [Related]
26. Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer.
Jaeger S; Igea A; Arroyo R; Alcalde V; Canovas B; Orozco M; Nebreda AR; Aloy P
Cancer Res; 2017 Jan; 77(2):459-469. PubMed ID: 27879272
[TBL] [Abstract][Full Text] [Related]
27. Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database.
Close DA; Wang AX; Kochanek SJ; Shun T; Eiseman JL; Johnston PA
SLAS Discov; 2019 Mar; 24(3):242-263. PubMed ID: 30500310
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of in vitro chemosensitivity using human lung cancer cell lines.
Kratzke RA; Kramer BS
J Cell Biochem Suppl; 1996; 24():160-4. PubMed ID: 8806098
[TBL] [Abstract][Full Text] [Related]
29. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
30. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
31. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
33. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
[TBL] [Abstract][Full Text] [Related]
34. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro.
Chou TC
Contrib Gynecol Obstet; 1994; 19():91-107. PubMed ID: 7995057
[No Abstract] [Full Text] [Related]
35. Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Gowda R; Sharma A; Robertson GP
Cancer Lett; 2017 Jan; 385():243-250. PubMed ID: 27769779
[TBL] [Abstract][Full Text] [Related]
36. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.
Rytelewski M; Buensuceso A; Leong HS; Deroo BJ; Chambers AF; Koropatnick J
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741641
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
[TBL] [Abstract][Full Text] [Related]
40. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
